A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB).

Activity: Talk or presentationTalk or presentation at a conference

Period26 Mar 2022
Event titleBSN annual meeting
Event typeConference
Degree of RecognitionNational